Recursion Pharmaceuticals (RXRX -15.70%) didn't have a fine start to the working week on Monday, at least as far as its stock was concerned. Investors traded out of it following the clinical-stage biotech's first-quarter earnings release and business update, and the share price was down by 15% in mid-session trading. The S&P 500 index was doing comparatively better, with a 0.3% decline. Light revenue and a deepening net lossFor the quarter, Recursion -- which although a clinical-stage company earns some coi ...

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.64%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.36 per share when it actually produced a loss of $0.53, delivering a surprise of -47.22%.Over the last four quarters ...

Recursion Pharmaceuticals (RXRX) Q1 2025 Earnings Call May 05, 2025 08:00 AM ET Speaker0 Hi, everybody. My name is Chris Gibson, cofounder and CEO of Recursion, and I'm delighted to welcome you to our learnings call this morning. We're gonna go ahead and get started. Perfect. So, of course, important to note that we're gonna be providing forward looking information today, so please understand all of these important caveats. So I wanna begin by just talking a little bit about Recursion's mission, which is to ...

Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40323 UNITED STATES SECURITIES AND EXCHANGE COMMISSION RECURSION PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 46-4099738 (State or othe ...

Exhibit 99.1 Recursion Reports First Quarter 2025 Financial Results and Provides Business Update SALT LAKE CITY, May 5, 2025 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates financial results for its first quarter ending March 31, 2025. Recursion will host a L(earnings) Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm BST from Recursion's X (formerly Twitter), LinkedIn, and YouTube accou ...

Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing 3 clinical programs and 1 preclinical program following a strategic, data-driven reviewPartnerships: Achieved fourth milestone in Sanofi collaboration, generating $7 million for an orally active small-molecule lead with best-in-class potential in autoimmune diseasesPlatform and Operations: Implemented meaningful s ...

Group 1 - The core viewpoint is that artificial intelligence (AI) is not a passing trend but is increasingly integrated into various sectors, including healthcare [2] - AI is making significant advancements in healthcare, indicating its growing importance in the industry [2] - The investing group Compounding Healthcare focuses on innovative companies in biotech and life sciences, particularly those developing breakthrough therapies and pharmaceuticals [2] Group 2 - The article emphasizes the potential of AI to transform healthcare, suggesting that it will play a crucial role in future developments [2] - The leader of the investing group has a background in the medical field, which informs their investment strategy in healthcare [2]

Core Insights - Recursion announced preliminary safety and efficacy results from its Phase 1b/2 TUPELO trial of REC-4881, an investigational MEK1/2 inhibitor for Familial Adenomatous Polyposis (FAP) [1][5] Company Overview - Recursion is a clinical-stage TechBio company focused on decoding biology to improve lives, utilizing its Recursion OS platform to analyze biological and chemical datasets [23] - The company has received Fast Track and Orphan Drug designations from the U.S. FDA for REC-4881, which is aimed at treating FAP, a rare inherited disorder [2] Clinical Trial Details - The TUPELO trial is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of REC-4881 in patients with FAP [6][8] - The Phase 1b portion was a randomized, double-blind, placebo-controlled safety run-in, while the ongoing Phase 2 portion is open-label [7][8] Efficacy Results - As of March 17, 2025, REC-4881 treatment led to a preliminary median 43% reduction in polyp burden at Week 13 among six efficacy-evaluable patients [3][10] - Five out of six patients (83%) experienced reductions in polyp burden ranging from 31% to 82%, while one patient showed a 595% increase from baseline [3][10] - Three of six patients (50%) achieved a ≥1-point reduction in Spigelman stage, indicating improvement in disease severity [11] Safety Profile - Among 19 safety-evaluable patients, 79% experienced at least one treatment-related adverse event (TRAE), with the majority being Grade 1 or 2 [4][16] - The most frequent TRAEs included acneiform rash, diarrhea, and decreased left ventricular ejection fraction (LVEF) [4][17] - Grade 3 TRAEs occurred in 16% of patients, with no Grade ≥4 events reported [4][18] Next Steps - Patient enrollment in the TUPELO trial is ongoing, with additional efficacy and safety analyses anticipated in the second half of 2025 [21]

Company to host public (L)earnings call on May 5th at 8:00 am ET / 6:00 am MT / 1:00 pm GMTSalt Lake City, UT, April 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide business updates and report its first quarter 2025 financial results on Monday, May 5, 2025, before the open of the financial markets. Recursion will host a (L)earnings Call on May 5, 2025 at 8:00 am ET / 6:00 am MT / 1:00 ...

Core Insights - Recursion is set to present preliminary data from its Phase 1b/2 clinical trial, TUPELO, evaluating the safety and preliminary activity of REC-4881 for treating familial adenomatous polyposis (FAP) at the 2025 Digestive Disease Week meeting [1][2] - FAP is a rare hereditary condition affecting approximately 50,000 individuals across the US and Europe, with no FDA-approved therapies currently available [2][4] - REC-4881 is a non-ATP-competitive allosteric small molecule MEK 1/2 inhibitor identified through Recursion's AI-powered platform [3][4] Clinical Trial Details - The TUPELO trial is a multicenter, open-label study assessing REC-4881's efficacy, safety, and pharmacokinetics in patients with FAP post-colectomy/proctocolectomy [5] - As of February 7, 2025, 13 patients received 4 mg of REC-4881 daily, with 84.6% experiencing at least one treatment-related adverse event, primarily mild rashes [4] - Among 5 efficacy-evaluable patients, there was a greater than 30% median reduction in total polyp burden after 12 weeks of treatment [4] Upcoming Presentation - The presentation titled "Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy in Familial Adenomatous Polyposis (FAP): Preliminary Safety and Efficacy Data" is scheduled for May 4, 2025, from 9:15 AM to 9:30 AM PDT [5] Company Overview - Recursion is a clinical stage TechBio company focused on decoding biology to improve lives, utilizing its Recursion OS platform to analyze vast biological and chemical datasets [7][8] - The company operates one of the most powerful supercomputers globally, enabling extensive experimental and computational capabilities [8] - Recursion is headquartered in Salt Lake City and has multiple offices across North America and Europe [9]